Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you start immunotherapy in a patient with metastatic melanoma who is on steroids (e.g. dexamethasone for cerebral edema)?
Or would you try to wait and get the steroids off first?
Answer from: Medical Oncologist at Academic Institution
In general immunotherapy should not be started if patients require predisone or the equivalent more than 10 mg a day.
Sign in or Register to read more
2357
Related Questions
Would you consider adjuvant immunotherapy for a patient with high-risk (N3 nodes) Merkel cell carcinoma following definitive surgical resection and adjuvant radiation therapy?
How would you manage a cardiac metastasis from Merkel cell carcinoma?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
How would you sequence lifileucel (TIL therapy) in a patient with metastatic melanoma who is BRAF wild-type (BRAF WT) and progressed on adjuvant Nivolumab?
How do you approach the management of patients with locally advanced unresectable mucosal melanoma in the head and neck region?
How would you treat locally advanced melanoma of the scalp with several in transit lesions and a metastatic lesion to the parotid if the patient is progressing on immunotherapy such as pembrolizumab?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?
What is the role of adrenalectomy in managing isolated recurrence of stage IIIc melanoma, occurring 2 years after the original diagnosis, in a patient who declined adjuvant therapy?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?